Anavex Life Sciences: Fiscal Q1 Earnings Snapshot
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot
Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue...
The company's first-quarter earnings report detailed positive news regarding its pipeline.
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
The mean of analysts' price targets for Anavex Life Sciences (AVXL) points to a 270.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...